Health
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views New Be the first to read
Brief read Under 1 min brief 26 words
Summary
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Mothers' poor sleep quality in late pregnancy linked to higher obesity risk in their childrenContinue reading
- The rise of Big Toothbrush: how did our mouths become such a lucrative market?Continue reading
- First drug to treat Alexander disease approved by the FDA after three decades of researchContinue reading
- New global safety guidelines for diagnostic ultrasoundContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow